NCT03713086 - A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 12, 2018

Primary Completion Date

November 23, 2021

Study Completion Date

November 23, 2021

Conditions

Rabies

Interventions

BIOLOGICAL

Rabipur®

3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm

BIOLOGICAL

Rabies mRNA vaccine CV7202

CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm

BIOLOGICAL

Rabies mRNA vaccine CV7202

CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm

BIOLOGICAL

Rabies mRNA vaccine CV7202

CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm

Trial Locations (2)

University Hospital Ghent, Ghent

Department of Infectious Diseases and Tropical Medicine (DITM), Medical Center of the University of Munich, Munich